Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

156 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity.
Leskelä S, Jara C, Leandro-García LJ, Martínez A, García-Donas J, Hernando S, Hurtado A, Vicario JC, Montero-Conde C, Landa I, López-Jiménez E, Cascón A, Milne RL, Robledo M, Rodríguez-Antona C. Leskelä S, et al. Pharmacogenomics J. 2011 Apr;11(2):121-9. doi: 10.1038/tpj.2010.13. Epub 2010 Mar 9. Pharmacogenomics J. 2011. PMID: 20212519
Regulatory polymorphisms in β-tubulin IIa are associated with paclitaxel-induced peripheral neuropathy.
Leandro-García LJ, Leskelä S, Jara C, Gréen H, Avall-Lundqvist E, Wheeler HE, Dolan ME, Inglada-Perez L, Maliszewska A, de Cubas AA, Comino-Méndez I, Mancikova V, Cascón A, Robledo M, Rodríguez-Antona C. Leandro-García LJ, et al. Clin Cancer Res. 2012 Aug 15;18(16):4441-8. doi: 10.1158/1078-0432.CCR-12-1221. Epub 2012 Jun 20. Clin Cancer Res. 2012. PMID: 22718863 Free PMC article.
A Pilot, Phase II, Randomized, Open-Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab-Paclitaxel to That of Solvent-Based Paclitaxel as the First-Line Treatment for Patients with Human Epidermal Growth Factor Receptor Type 2-Negative Metastatic Breast Cancer.
Ciruelos E, Apellániz-Ruiz M, Cantos B, Martinez-Jáñez N, Bueno-Muiño C, Echarri MJ, Enrech S, Guerra JA, Manso L, Pascual T, Dominguez C, Gonzalo JF, Sanz JL, Rodriguez-Antona C, Sepúlveda JM. Ciruelos E, et al. Oncologist. 2019 Nov;24(11):e1024-e1033. doi: 10.1634/theoncologist.2017-0664. Epub 2019 Apr 25. Oncologist. 2019. PMID: 31023863 Free PMC article. Clinical Trial.
PharmVar GeneFocus: CYP3A5.
Rodriguez-Antona C, Savieo JL, Lauschke VM, Sangkuhl K, Drögemöller BI, Wang D, van Schaik RHN, Gilep AA, Peter AP, Boone EC, Ramey BE, Klein TE, Whirl-Carrillo M, Pratt VM, Gaedigk A. Rodriguez-Antona C, et al. Clin Pharmacol Ther. 2022 Dec;112(6):1159-1171. doi: 10.1002/cpt.2563. Epub 2022 Mar 29. Clin Pharmacol Ther. 2022. PMID: 35202484 Free PMC article. Review.
Whole-exome sequencing reveals defective CYP3A4 variants predictive of paclitaxel dose-limiting neuropathy.
Apellániz-Ruiz M, Lee MY, Sánchez-Barroso L, Gutiérrez-Gutiérrez G, Calvo I, García-Estévez L, Sereno M, García-Donás J, Castelo B, Guerra E, Leandro-García LJ, Cascón A, Johansson I, Robledo M, Ingelman-Sundberg M, Rodríguez-Antona C. Apellániz-Ruiz M, et al. Clin Cancer Res. 2015 Jan 15;21(2):322-8. doi: 10.1158/1078-0432.CCR-14-1758. Epub 2014 Nov 14. Clin Cancer Res. 2015. PMID: 25398452
Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel--letter.
Apellániz-Ruiz M, Sánchez-Barroso L, Gutiérrez-Gutiérrez G, Sereno M, García-Donás J, Åvall-Lundqvist E, Gréen H, Brøsen K, Bergmann TK, Rodríguez-Antona C. Apellániz-Ruiz M, et al. Clin Cancer Res. 2015 Jul 1;21(13):3092-3. doi: 10.1158/1078-0432.CCR-14-1885. Clin Cancer Res. 2015. PMID: 26133776 No abstract available.
156 results